{{Rsnum
|rsid=181736
|Gene=PDE4D
|Chromosome=5
|position=59381407
|Orientation=plus
|GMAF=0.3889
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PDE4D
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 20.4 | 42.5 | 37.2
| HCB | 20.4 | 41.6 | 38.0
| JPT | 17.7 | 45.1 | 37.2
| YRI | 10.9 | 53.7 | 35.4
| ASW | 8.8 | 52.6 | 38.6
| CHB | 20.4 | 41.6 | 38.0
| CHD | 16.5 | 45.0 | 38.5
| GIH | 10.9 | 42.6 | 46.5
| LWK | 9.1 | 50.0 | 40.9
| MEX | 5.2 | 44.8 | 50.0
| MKK | 10.3 | 42.9 | 46.8
| TSI | 12.7 | 51.0 | 36.3
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs181736
|Name_s=
|Gene_s=PDE4D
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00002. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109445
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs181736
|overall_frequency_n=40
|overall_frequency_d=126
|overall_frequency=0.31746
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=42
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}